Reduction of urinary basic fibroblast growth factor using pentosan polysulphate sodium.

Objective: To evaluate the use of pentosan polysulphate sodium (PPS) to reduce the level of urinary basic fibroblast growth factor (bFGF).

Patients And Methods: Forty-one patients with a clam enterocystoplasty were randomized to receive either 200 mg three times daily of oral PPS (n = 21) or placebo (n = 20) for 6 weeks. Three patients acted as a cross-over study.

Elevated levels of basic fibroblast growth factor in the urine of clam enterocystoplasty patients.

Purpose: We determined whether basic fibroblast growth factor is elevated in the urine of patients who have undergone clam ileocystoplasty.

Materials And Methods: An immunoassay technique was used to measure urinary basic fibroblast growth factor in 50 patients equally divided between those with and without neuropathy who had undergone clam enterocystoplasty. The results were compared with urinary basic fibroblast growth factor concentrations from 25 healthy age and sex matched volunteers.